Circadian effects in cancer-relevant psychoneuroendocrine and immune pathways

Eismann, Emily A.; Lush, Elizabeth; Sephton, Sandra E.

doi:10.1016/j.psyneuen.2009.12.011

Cited by 81 publications

(64 citation statements)

References 176 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cancer patients take longer time to fall asleep, wake up more often, spend more time in bed and nap more frequently than healthy individuals [32,33] . On the other hand, genetic, environmental or behavioral factors may favor circadian disruption, predisposing patients to tumor development [34] . Several studies have demonstrated that long-term night shiftwork is a prognostic value for breast cancer [35,36] .…”

Section: Discussionmentioning

confidence: 99%

Association between PER3 length polymorphism and onco-hematological diseases and its influences on fatigue on awakening in patients

et al. 2015

View full text Add to dashboard Cite

Circadian clock gene PER3 and its length polymorphism may have a role in oncogenesis as clock genes act as key regulators of cell cycle and DNA repair pathways. The polymorphism may affect the condition of patients who show disrupted circadian rhythm due to tumor development. The aim was to assess the association between PER3 polymorphism and onco-hematological diseases, and analyze whether this variant has an impact on patient's functionality. We conducted a case-control study on 125 patients with onco-hematological diseases and 310 control patients. PER3 allelic variants were detected by using polymerase chain reaction. Sociodemographic data and information on patient's habits and functionality were obtained through questionnaire. Genotypes 4/5 + 5/5 showed an odd ratio (OR) = 1.39, with no statistical significance. However, those genotypes were associated with a two-fold increase in the risk of acute/chronic lymphoblastic/myeloblastic leukemia, taken all together. The occurrence of "changes in humor during last two months" was significantly associated with onco-hematological diseases. "Fatigue on awakening" and "self-reported snore" were associated with cases carrying the 4/5 or 5/5 genotypes. The results suggested that PER3 polymorphism may have a role in the risk of leukemia, and might be a possible marker for individual differences in susceptibility to sleep disruption. This work provides insights for the identification of individuals at high risk of cancer, and those who are more susceptible to circadian disruption, which may decrease the physiological defenses against the tumor. he circadian system regulates metabolism and energy homeostasis on a daily basis in order to maintain vital processes and prepare the organism to respond to predictable/daily environmental conditions [1] . Accordingly, most of the mammalian physiology is regulated at some points by the main circadian clock which is located at the hypothalamic suprachiasmatic nuclei (SCN). Circadian coordination is known to be T

show abstract

Section: Discussionmentioning

confidence: 99%

Association between PER3 length polymorphism and onco-hematological diseases and its influences on fatigue on awakening in patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Synthetic glucocorticoids administered at therapeutic doses, used either as anticancer agents or for supportive care (used for their antiemetic or immunosuppressive properties), can disrupt physiological diurnal cortisol rhythms, thus altering the circadian component of sleep 59,73. Finally, newer targeted agents, such as small tyrosine-kinase inhibitors, could act specifically in the central nervous system, modifying the effect of neuroendocrine cytokines and growth factors on sleep–wake and rest–activity cycles 63,74. Gefitinib, for example, an oral epidermal growth factor receptor (EGFR) inhibitor, has been shown to improve circadian rest-activity rhythm regardless of its antitumor effects in patients with advanced non-small cell lung cancer 75.…”

Section: Biological Mechanisms Contributing To Chemotherapy-associatementioning

confidence: 99%

Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer

Palesh¹,

Peppone²,

Innominato³

et al. 2012

NSS

129

122

View full text Add to dashboard Cite

Sleep problems are highly prevalent in cancer patients undergoing chemotherapy. This article reviews existing evidence on etiology, associated symptoms, and management of sleep problems associated with chemotherapy treatment during cancer. It also discusses limitations and methodological issues of current research. The existing literature suggests that subjectively and objectively measured sleep problems are the highest during the chemotherapy phase of cancer treatments. A possibly involved mechanism reviewed here includes the rise in the circulating proinflammatory cytokines and the associated disruption in circadian rhythm in the development and maintenance of sleep dysregulation in cancer patients during chemotherapy. Various approaches to the management of sleep problems during chemotherapy are discussed with behavioral intervention showing promise. Exercise, including yoga, also appear to be effective and safe at least for subclinical levels of sleep problems in cancer patients. Numerous challenges are associated with conducting research on sleep in cancer patients during chemotherapy treatments and they are discussed in this review. Dedicated intervention trials, methodologically sound and sufficiently powered, are needed to test current and novel treatments of sleep problems in cancer patients receiving chemotherapy. Optimal management of sleep problems in patients with cancer receiving treatment may improve not only the well-being of patients, but also their prognosis given the emerging experimental and clinical evidence suggesting that sleep disruption might adversely impact treatment and recovery from cancer.

show abstract

“…Levels of wakefulness-promoting factors such as orexin, ghrelin, adrenocorticotrophin hormone, and corticotrophin-releasing hormone have all been found to be abnormal in HD (136). Consequences of sleep deprivation including stress, depression, reduced immunity, memory and learning impairments, and metabolic and hormonal abnormalities are all likely to further exacerbate HD-related pathophysiology across the whole body (137–140). …”

Section: Huntington’s Diseasementioning

confidence: 99%

Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System

et al. 2014

View full text Add to dashboard Cite

With our increasing appreciation of the true complexity of diseases and pathophysiologies, it is clear that this knowledge needs to inform the future development of pharmacotherapeutics. For many disorders, the disease mechanism itself is a complex process spanning multiple signaling networks, tissues, and organ systems. Identifying the precise nature and locations of the pathophysiology is crucial for the creation of systemically effective drugs. Diseases once considered constrained to a limited range of organ systems, e.g., central neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’ disease (HD), the role of multiple central and peripheral organ systems in the etiology of such diseases is now widely accepted. With this knowledge, it is increasingly clear that these seemingly distinct neurodegenerative disorders (AD, PD, and HD) possess multiple pathophysiological similarities thereby demonstrating an inter-related continuum of disease-related molecular alterations. With this systems-level appreciation of neurodegenerative diseases, it is now imperative to consider that pharmacotherapeutics should be developed specifically to address the systemic imbalances that create the disorders. Identification of potential systems-level signaling axes may facilitate the generation of therapeutic agents with synergistic remedial activity across multiple tissues, organ systems, and even diseases. Here, we discuss the potentially therapeutic systems-level interaction of the glucagon-like peptide 1 (GLP-1) ligand–receptor axis with multiple aspects of the AD, PD, and HD neurodegenerative continuum.

show abstract

Circadian effects in cancer-relevant psychoneuroendocrine and immune pathways

Cited by 81 publications

References 176 publications

Association between PER3 length polymorphism and onco-hematological diseases and its influences on fatigue on awakening in patients

Association between PER3 length polymorphism and onco-hematological diseases and its influences on fatigue on awakening in patients

Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer

Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System

Contact Info

Product

Resources

About